KDM6A and breast cancer: However, pharmacological inhibition of KDM6A by GSKJ4, a H3K27me3 demethylase inhibitor toward JMJD3 and UTX, overcomes the paclitaxel-induced BC stem cell enrichment (Yan et al., 2017; Lu H. et al., 2020).